Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

The estimated patent date of Remicade and Rituxan

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
rwdm Member Profile
 
Followed By 2
Posts 73
Boards Moderated 0
Alias Born 07/19/10
160x600 placeholder
S&P 500 Posts Biggest Weekly Gain Of 2014
U.S. stocks closed with solid gains Friday, leaving the S&P 500 with its largest weekly advance of the year.
Top Equities Stories Of The Day
European Markets Show Signs of Stress--2nd Update
Microsoft Gains Help Lead Tech's Advance
Treasury Bonds Pull Back for Second Straight Day
Will Free Data Become the Next Free Shipping?
Microsoft Braces for Another Nokia Hit--Earnings Preview
Procter & Gamble Looking at Margins, Brands--Earnings Preview
Pfizer Results Will Play Second Fiddle to Dealmaking Outlook -- Earnings Preview
Stifel Financial to Hire Two Former Merrill Lynch Advisers
rwdm   Thursday, 07/29/10 02:07:10 PM
Re: None
Post # of 183180 
The estimated patent date of Remicade and Rituxan in Europe are 2014 and 2015 respectively. In the US both expiry dates are in 2018. Is this because of Genentech's Cabily patent? If yes, does this mean that the expiry date of most of the mabs in US is 2018?

Is Teva's Rituximab TL011, which is starting nowadays clinical trials, in the regulatory pathway of BLA or as a biosimilar?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist